Accession Number:

ADA341569

Title:

Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin.

Descriptive Note:

Annual rept. 23 Sep 96-22 Sep 97,

Corporate Author:

TEXAS UNIV AT HOUSTON

Personal Author(s):

Report Date:

1997-10-01

Pagination or Media Count:

58.0

Abstract:

Annamycin is a non-cross resistant doxorubicin analog that is formulated in a liposomal carrier. We have completed a phase I study and initiated a phase II study of liposomal Annamycin in patients with metastatic breast carcinoma. The maximum tolerated dose was 210mgm2. The limiting toxicity was myelosuppression. Other toxicities were limited to allergic reactions. No significant cardiotoxicity, alopecia, mucositis, nor gastrointestinal toxicity have been observed. No antitumor responses were observed in the Phase I study. Three patients have been accrued in the Phase II study. Tumor tissue is being stored for determination of MDR-1 and MRP status at baseline and after therapy.

Subject Categories:

  • Biochemistry
  • Anatomy and Physiology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE